Gansevoort MD - Pulse Biosciences Chief Officer
| PLSE Stock | USD 19.63 1.84 10.34% |
Executive
Gansevoort MD is Chief Officer of Pulse Biosciences
| Address | 3957 Point Eden Way, Hayward, CA, United States, 94545 |
| Phone | 510 906 4600 |
| Web | https://www.pulsebiosciences.com |
Pulse Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 4, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Pulse Biosciences' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 26.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Douglas Seith | AtriCure | 59 | |
| Kerri DiPietro | Haemonetics | N/A | |
| Stefano Taucer | OraSure Technologies | N/A | |
| David CFA | OraSure Technologies | N/A | |
| Christopher Pazdan | Repro Med Systems | N/A | |
| John Landry | Nyxoah | 52 | |
| Jan MD | Haemonetics | N/A | |
| Trace Custer | OraSure Technologies | N/A | |
| Niro Ramachandran | Akoya Biosciences | 50 | |
| David Hissong | LeMaitre Vascular | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| Andy Molnar | Milestone Scientific | 62 | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Paul Grass | Akoya Biosciences | N/A | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Jonathan Ngau | LeMaitre Vascular | 51 | |
| James JD | Milestone Scientific | N/A | |
| Mikaela Kirkwood | Nyxoah | N/A | |
| Remi Renard | Nyxoah | N/A | |
| Priyam Shah | Akoya Biosciences | N/A | |
| Zachary Wert | OraSure Technologies | N/A | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 |
Pulse Biosciences Leadership Team
Elected by the shareholders, the Pulse Biosciences' board of directors comprises two types of representatives: Pulse Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulse. The board's role is to monitor Pulse Biosciences' management team and ensure that shareholders' interests are well served. Pulse Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulse Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patty Perla, Vice Resources | ||
| Robert Duggan, Executive CoChairman | ||
| Sandra Gardiner, CFO Admin | ||
| JD Esq, General Secretary | ||
| Gansevoort MD, Chief Officer | ||
| Niv MD, Chief Surgery | ||
| Richard Nuccitelli, Chief Officer | ||
| Darrin Uecker, Principal CTO | ||
| Kevin Danahy, President CEO | ||
| Mitchell Levinson, Chief Director | ||
| Holly JD, VP Strategy | ||
| Burke Barrett, CEO President | ||
| David Danitz, Senior Engineering | ||
| Edison Manuel, Vice Operations |
Pulse Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulse Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 61.52 M | ||||
| Shares Owned By Insiders | 71.93 % | ||||
| Shares Owned By Institutions | 9.31 % | ||||
| Number Of Shares Shorted | 2.17 M | ||||
| Price To Earning | (22.54) X | ||||
| Price To Book | 15.26 X | ||||
| Price To Sales | 60.23 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulse Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.